With the FDA likely to authorize Pfizer’s COVID-19 vaccine for children between the ages of 6 months and 5, the last major phase of the U.S. vaccination roll-out may soon be underway. This brief provides an overview of the characteristics of children under the age of 5 and discusses some issues to consider in rolling out vaccination to this age group.
